Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danshen Gegen in peripheral arterial disease
NCT02380794Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of salvia miltiorrhiza + pueraria lobata in Peripheral Arterial Disease (PAD), intermittent claudication (IC), sponsored by The Chinese University of Hong Kong. Started Oct 2015; status: completed.
02
Drugs
salvia miltiorrhiza + pueraria lobata
03
Conditions
Peripheral Arterial Disease (PAD)intermittent claudication (IC)
Beyond the preview
Go deeper on NCT02380794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380794.